Invokana KDIGO Guidelines

Prescribing Information

Great Britain Northern Ireland

Guideline Recommendations

SGLT2 inhibitors are now recommended alongside metformin for patients with type 2 diabetes, chronic kidney disease and eGFR ≥30 mL/min/1.73 m² at initiation in the KDIGO guidelines.¹

Adapted from: KDIGO clinical practice guideline on diabetes management in chronic kidney disease. 2020.¹

CREDENCE Study

Abbreviations

CKD: Chronic Kidney Disease; DPP-4: Dipeptidyl Peptidase 4; eGFR: estimated Glomerular Filtration Rate; GLP-1: Glucagon-Like Peptide 1; KDIGO: Kidney Disease: Improving Global Outcomes; SGLT2i: Sodium-Glucose Co-transporter 2 inhibitor; T2DM: Type 2 Diabetes Mellitus; TZD: Thiazolidinedione.

References

KDIGO. KDIGO clinical practice guideline on diabetes management in chronic kidney disease. October 2020. Available at: https://kdigo.org/wp-content/uploads/2020/10/KDIGO-2020-Diabetes-in-CKD-GL.pdf [Accessed December 2021].

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyuk@napp.co.uk.